The Sentinel

THE OFFICIAL BLOG OF THE SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC).

Tuesday, July 24, 2018

JITC Earns Impact Factor of 8.374



The impact factor is a critically important calculation involving the number of citations published articles received during a two-year timeline. Thus, this figure readily communicates to prospective authors the relative reach and quality of research a publication possesses.

Even before the publication of its impact factor, awareness of JITC had reached new heights in 2018, as submissions had already increased by 65 percent over last year. We know our 8.374 impact factor is merely a starting point from which JITC will grow in sync with the steady expansion of research and translation in the field of immuno-oncology. The number of submissions will multiply; the quality and breadth of research will increase; JITC will become an even stronger open access, peer-reviewed online journal.

I’d like to take this opportunity to thank all of JITC’s Section Editors, Associate Editors and reviewers who generously give so much of their time to ensure the journal publishes only the highest quality research in the field of cancer immunotherapy and tumor immunology.

Lastly, please take a moment to remember and celebrate the life and work of Harald von Boehmer who sadly passed away late last month. His contributions to the understanding of the T cell receptor’s key role in T cell development, differentiation, and central tolerance induction are part of the foundations of our current understanding of tumor immunology.

With best regards,
Pedro J. Romero, MD
Editor-in-Chief, Journal for ImmunoTherapy of Cancer